Close Menu

NEW YORK (GenomeWeb) – Aldatu Biosciences is expanding its team in anticipation of initiating end-user evaluations next year of its genetic test for antiviral-resistant strains of HIV in select countries in Southern Africa.

The Cambridge, Massachusetts-based startup, which recently became a registered public-benefit corporation, also received funding from a foundation focused on child health and is hoping to attract additional mission-driven investors in the future.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.